< Back to previous page
Researcher
Peter Carmeliet
- Disciplines (Flanders Institute for Biotechnology):Analysis of next-generation sequence data, Cell death, Cancer biology
- Disciplines (KU Leuven):Cardiac and vascular medicine
- See also: Peter Carmeliet (Flanders Institute for Biotechnology)
Affiliations
- Laboratory of Angiogenesis and Vascular Metabolism (VIB-KU Leuven) (Division)
Responsible
From1 Jan 2012 → Today - Carmeliet Lab (Research group)
Responsible
From1 Jan 2017 → Today - Laboratory of Angiogenesis and Vascular Metabolism (VIB-KU Leuven) (Division)
Member
From1 Jan 2012 → Today - Centre for Molecular and Vascular Biology (Division)
Member
From1 Oct 1999 → 30 Sep 2005
Projects
11 - 20 of 110
- Single cell investigation of intussusceptive angiogenesis in health and disease.From1 Oct 2021 → TodayFunding: FWO senior postdoctoral fellowship
- The neurovascular link: an unexpectedly important role of metabolism.From1 Oct 2021 → TodayFunding: BOF - Methusalem
- INFECT: exploratIoN oF (epi)-gEnetic changes Contributing To long COVID-19From1 Oct 2021 → TodayFunding: FWO junior postdoctoral fellowship
- Defining and exploiting the endothelial cell heterogeneity in pulmonary vasculature of patients with pulmonary arterial hypertension (PAH)From3 Aug 2021 → TodayFunding: Own budget, for example: patrimony, inscription fees, gifts
- Driving endothelial cell specification in pluripotent stem cells and identifying organ(oid) specific vascularization for regenerative medicineFrom5 Jul 2021 → TodayFunding: Own budget, for example: patrimony, inscription fees, gifts
- The potential of innovative genome-scale metabolic models in discovering novel targets to treat pathological angiogenesisFrom1 Jan 2021 → TodayFunding: FWO research project (including WEAVE projects)
- The endothelium is a central mediator of cystic fibrosis lung diseaseFrom20 Nov 2020 → 24 May 2022Funding: Own budget, for example: patrimony, inscription fees, gifts
- Tumor endothelial cells: gatekeepers and overlooked targets of anti-tumor immunity-implications for alternative immunotherapy?From1 Nov 2020 → 31 Aug 2021Funding: FWO junior postdoctoral fellowship
- Pathological vessel remodelling in hepatocellular carcinoma: a single cell and spatially resolved transcriptome and interactome study to identify new targetsFrom1 Nov 2020 → 28 Feb 2022Funding: FWO fellowships
- Unleashing CRISPR technologies to find novel tumor vessel tuning strategiesFrom1 Oct 2020 → 9 Aug 2022Funding: FWO junior postdoctoral fellowship
Publications
1 - 10 of 587
- Fatty acid oxidation fuels natural killer cell responses against infection and cancer.(2024)
Authors: Peter Carmeliet
Pages: e231925412 - Targeting hypoxia-inducible factors: therapeutic opportunities and challenges(2024)
Authors: Peter Carmeliet
- Editorial Expression of Concern: The netrin receptor UNC5B mediates guidance events controlling morphogenesis of the vascular system.(2024)
Authors: Peter Carmeliet
Pages: E12 - The Receptor Tyrosine Kinase AXL Is Required at Multiple Steps of the Metastatic Cascade during HER2-Positive Breast Cancer Progression (vol 23, pg 1476, 2018)(2023)
Authors: Peter Carmeliet
- Detailed protocol for a corneal thermal cauterization-based (lymph-)angiogenesis assay in mice(2023)
Authors: Anh-Co Truong, Koen Veys, Mieke Dewerchin, Peter Carmeliet
- Glucose Controls Glucagon Secretion by Regulating Fatty Acid Oxidation in Pancreatic α-Cells(2023)
Authors: Peter Carmeliet
Pages: 1446 - 1459 - Renal Endothelial Cell Metabolism in Health and Acute Kidney Injury: a window for therapeutic opportunities(2023)
Authors: Mila Borri, Peter Carmeliet, Guy Eelen, Sébastien Dumas
- VEGF-B prevents excessive angiogenesis by inhibiting FGF2/FGFR1 pathway(2023)
Authors: Mieke Dewerchin, Peter Carmeliet
- PARTIAL MYELOID INHIBITION OF KEY GLYCOLYTIC ENZYME PFKFB3 INCREASES HEPATIC STEATOSIS AND INFLAMMATION, BUT DOES NOT AFFECT ATHEROSCLEROSIS(2023)
Authors: Peter Carmeliet
- Understanding tumour endothelial cell heterogeneity and function from single-cell omics(2023)
Authors: Peter Carmeliet
Pages: 544 - 564
Patents
1 - 10 of 10
- Carnitine palmitoyltransferase 1 inhibitors for inhibition of pathological angiogenesis (Inventor)
- Extracellular allosteric inhibitor binding domain from a tyrosine kinase receptor (Inventor)
- Inhibition of plgf to treat philadelphia chromosome positive leukemia (Inventor)
- Means and methods for treating lung hypoplasia (Inventor)
- Use of VEGF and homologues to treat neuron disorders (Inventor)
- Novel anti-PLGF antibody (Inventor)
- Anti-angiogenic therapy (Inventor)
- Responsiveness to angiogenesis inhibitors (Inventor)
- CARNITINE PALMITOYLTRANSFERASE 1 INHIBITORS FOR INHIBITION OF PATHOLOGICAL ANGIOGENESIS (Inventor)
- GLUTAMINE SYNTHETASE INHIBITORS FOR INHIBITION OF PATHOLOGICAL ANGIOGENESIS (Inventor)